Tempest Therapeutics (TPST) Liabilities and Shareholders Equity (2011 - 2026)

Tempest Therapeutics has reported Liabilities and Shareholders Equity for 15 years, with the latest figure at $16.9 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 59.19% year-over-year to $16.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $90.7 million (down 43.96% YoY) and the FY2025 annual result came in at $16.9 million, down 59.19% from the prior year.
• Liabilities and Shareholders Equity declined to $16.9 million in Q4 2025 per TPST's latest filing, from $17.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $75.5 million in Q2 2021 and troughed at $16.9 million in Q4 2025.
• A 5-year average of $46.6 million and a median of $43.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2023: Liabilities and Shareholders Equity jumped 220.33% in 2021, then plunged 62.03% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $73.2 million in 2021, then plunged by 37.07% to $46.1 million in 2022, then advanced by 11.96% to $51.6 million in 2023, then decreased by 19.6% to $41.5 million in 2024, then plunged by 59.19% to $16.9 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $16.9 million, $17.1 million, and $24.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.